Nemtabrutinib plus venetoclax versus standard add-on therapy
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 3 study tests whether adding nemtabrutinib to venetoclax works better than the usual next treatment approach (venetoclax plus rituximab) in people with relapsed or treatment-resistant CLL/SLL. It may help by improving how well the cancer responds after at least one prior therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed CLL/SLL that is active and needs treatment now.
- Your disease has come back or did not respond to at least one previous therapy.
- You must have evidence of disease burden (a way doctors can measure the cancer’s activity).
- Your body strength (ECOG) is 0 to 2, and you’re expected to live at least 3 months.
- You can take and keep oral medicine down (you can swallow and absorb pills).
- You must not have certain infections or conditions (like active hepatitis B or C, or infections needing IV antibiotics).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests nemtabrutinib (MK-1026), an oral medicine, in people with certain blood cancers that have come back or didn’t respond to earlier treatments. It aims to see how well the drug works and whether it is safe.
This clinical trial tests two oral medications, nemtabrutinib and venetoclax, given together to people with untreated CLL or SLL. The goal is to see if this combination effectively kills cancer cells and helps you stay in remission with manageable side effects.
This trial tests a new drug, nemtabrutinib, against two standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment yet. The goal is to see if the new drug works better at controlling the disease.
This trial tests a combination of three drugs—nemtabrutinib, venetoclax, and obinutuzumab—for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if this combination is safe and effective in treating the disease.
This study tests a new oral medication, nemtabrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that did not respond to or stopped responding to certain targeted therapies. The medication aims to control the disease when other options have not worked.
This Phase 2 trial tests a combination of three medicines to treat chronic lymphocytic leukemia (CLL) that has not been treated before and where the goal is to achieve very low remaining disease. It may help some people stay in remission longer, but eligibility depends on your age, organ function, and prior treatments.
Hear when a new Leukemia, Lymphocytic, Chronic, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.